VELIPARIB for Breast cancer metastatic: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 8 adverse event reports in the FDA FAERS database where VELIPARIB was used for Breast cancer metastatic.
Most Reported Side Effects for VELIPARIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Neutrophil count decreased | 124 | 31.7% | 7 | 67 |
| Anaemia | 118 | 30.2% | 6 | 63 |
| White blood cell count decreased | 94 | 24.0% | 6 | 53 |
| Febrile neutropenia | 76 | 19.4% | 0 | 69 |
| Platelet count decreased | 70 | 17.9% | 6 | 37 |
| Hypertension | 57 | 14.6% | 3 | 33 |
| Nausea | 46 | 11.8% | 2 | 38 |
| Hyponatraemia | 38 | 9.7% | 4 | 22 |
| Vomiting | 36 | 9.2% | 1 | 30 |
| Hypokalaemia | 31 | 7.9% | 3 | 25 |
| Dehydration | 29 | 7.4% | 4 | 25 |
| Abdominal pain | 24 | 6.1% | 1 | 23 |
| Diarrhoea | 23 | 5.9% | 1 | 20 |
| Fatigue | 23 | 5.9% | 0 | 16 |
| Embolism | 19 | 4.9% | 1 | 13 |
Other Indications for VELIPARIB
Ovarian epithelial cancer (97)
Triple negative breast cancer (67)
Colorectal cancer (39)
Breast cancer (24)
Fallopian tube cancer (21)
Ovarian cancer (16)
Colorectal cancer metastatic (14)
Malignant peritoneal neoplasm (11)
Neoplasm (9)
Cervix carcinoma recurrent (8)
Other Drugs Used for Breast cancer metastatic
PALBOCICLIB (18,160)
RIBOCICLIB (9,771)
LETROZOLE (6,856)
TRASTUZUMAB (6,303)
FULVESTRANT (4,570)
PERTUZUMAB (3,784)
CAPECITABINE (3,691)
PACLITAXEL (3,241)
DOCETAXEL (3,070)
EVEROLIMUS (2,751)